A Phase 2 trial of a 6-week treatment schedule of neoadjuvant nivolumab and ipilimumab in operable MSI high or POLE exonuclease domain mutant colon cancer (CRC).

Biography

Professor  Agnieszka Michael MRCP PhD specialises in the field of Oncology, she is a researcher and a medical oncology consultant at the Royal Surrey NHS Foundation Trust. Professor Michael specialises in ovarian and renal cancers as well as immunotherapy trials. She qualified in medicine at the University of Wroclaw and undertook general medical and oncology training at the London Medical Oncology rotation , in St George's Hospital, London , Royal Marsden Hospital and Guy's and St Thomas' Hospital.  She was awarded a PhD for research in Cancer Immunotherapy by St George's, University of London, and continues to contribute to this field of research. Throughout her career Professor Michael has worked in the cancer clinical trials' field, including early phase studies with novel immunotherapy agents, gene therapy and cancer vaccines as well as international multi-centre phase III and IV studies, as a Chief investigator and a local Principal Investigator. Professor Michael is a Medical Director for Surrey Clinical Trials Unit and a Clinical Lead for National Ovarian Cancer Audit, as well as a deputy Chair of a Gynaecological Oncology Research subgroup hosted by  National Cancer Research Institute. 

See profile